Phase 3CompletedINTERVENTIONAL
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
ClinicalTrials.gov · NCT00210457 · Registry updated: 2020-03-31
- Condition / research focus
- Acromegaly
- Sponsor
- Ipsen
- Countries with listed sites
- France · Switzerland
- Registry dates and results
- Start: 2000-09. Completion: 2002-07-15 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Lanreotide (Autogel formulation) (drug)
Where the study takes place — 17 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Hôpital Sud
Amiens, France
Site recruitment: Not reported - Chu d'Angers
Angers, France